Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-31.16%||Sales Growth - Q/Q||-33.76%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-0.97%||ROE||-2.21%||ROI||-1.29%|
|Current Ratio||2.51||Quick Ratio||2.15||Long Term Debt/Equity||1.06||Debt Ratio||0.35|
|Gross Margin||62.22%||Operating Margin||-13.51%||Net Profit Margin||-3.29%||Dividend Payout Ratio|
|Cash From Financing Activities||397.92 M||Cash From Investing Activities||-119.38 M||Cash From Operating Activities||-41.03 M||Gross Profit||53.47 M|
|Net Profit||-46.59 M||Operating Profit||-78.99 M||Total Assets||2.29 B||Total Current Assets||881.74 M|
|Total Current Liabilities||351.44 M||Total Debt||562.73 M||Total Liabilities||1.29 B||Total Revenue||90.47 M|
|High 52 week||40.94||Low 52 week||17.26||Last close||32.99||Last change||-0.33%|
|RSI||56.73||Average true range||1.19||Beta||0.98||Volume||390.36 K|
|Simple moving average 20 days||5.28%||Simple moving average 50 days||13.25%||Simple moving average 200 days||20.43%|
|Performance Week||1.7%||Performance Month||19.83%||Performance Quart||33.19%||Performance Half||44.69%|
|Performance Year||2.68%||Performance Year-to-date||72.36%||Volatility daily||2.03%||Volatility weekly||4.53%|
|Volatility monthly||9.29%||Volatility yearly||32.17%||Relative Volume||137.41%||Average Volume||984.74 K|
|New High||New Low|
2019-06-18 09:58:01 | Alnylam Completes Enrollment in Phase III Study of Lumasiran
2019-06-18 08:06:33 | See what the IHS Markit Score report has to say about Medicines Co.
2019-06-17 19:15:51 | Did Hedge Funds Drop The Ball On Medicines Company MDCO?
2019-06-13 12:21:10 | Signal Says This Drug Stock Isn't Done Climbing
2019-06-13 08:02:51 | See what the IHS Markit Score report has to say about Medicines Co.
2019-06-06 15:28:07 | Alnylam Completes Rolling NDA Submission to FDA for Givosiran
2019-06-04 12:50:10 | These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming
2019-06-04 08:56:12 | Options Traders Expect Huge Moves in Medicines Company MDCO Stock
2019-06-04 08:02:27 | See what the IHS Markit Score report has to say about Medicines Co.
2019-06-03 16:48:08 | Alnylam Initiates Phase I Study on Hypertension Candidate
2019-06-03 06:43:04 | Notable Insider Buys This Past Week: Coty, Zillow and More
2019-06-01 08:03:22 | See what the IHS Markit Score report has to say about Medicines Co.
2019-05-25 09:31:01 | Medicines Co. MDCO Up 17.1% Since Last Earnings Report: Can It Continue?
2019-05-20 09:42:09 | Medicines Company Rallies On Positive LDL Cholesterol Study Results
2019-05-14 11:45:31 | See what the IHS Markit Score report has to say about Medicines Co.
2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
2019-05-07 08:06:37 | See what the IHS Markit Score report has to say about Medicines Co.
2019-05-02 13:20:07 | Did Hedge Funds Drop The Ball On The Medicines Company MDCO ?
2019-05-02 10:00:02 | Alnylam ALNY Reports Narrower-Than-Expected Loss in Q1
2019-05-01 10:03:35 | 4 ‘Strong Buy’ Stocks With Plenty Of Upside Ahead
2019-04-26 11:11:03 | Medicines Company MDCO Q1 Loss Narrows, Inclisiran in Focus
2019-04-26 08:35:39 | Medicines Co.: 1Q Earnings Snapshot
2019-04-26 07:29:54 | Medicines Co MDCO Q1 2019 Earnings Call Transcript
2019-04-26 01:36:07 | Edited Transcript of MDCO earnings conference call or presentation 25-Apr-19 12:30pm GMT
2019-04-18 07:00:00 | The Medicines Company to Announce First Quarter 2019 Financial Results on April 25
2019-04-17 10:32:02 | Medicines Co. MDCO May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2019-04-16 19:13:11 | Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
2019-04-15 16:49:08 | Alnylam ALNY Reports Phase III ENVISION Data on Givosiran
2019-04-12 08:49:12 | Implied Volatility Surging for Medicines Company MDCO Stock Options
2019-04-09 10:48:46 | See what the IHS Markit Score report has to say about Medicines Co.
2019-04-02 11:53:45 | See what the IHS Markit Score report has to say about Medicines Co.
2019-03-26 08:26:21 | See what the IHS Markit Score report has to say about Medicines Co.
2019-03-19 08:34:05 | See what the IHS Markit Score report has to say about Medicines Co.
2019-03-18 18:51:10 | Alnylam's ALNY Impressive Pipeline Drives Share Price
2019-03-15 16:24:16 | Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
2019-03-12 10:18:02 | Implied Volatility Surging for Medicines Company MDCO Stock Options
2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK
2019-03-10 19:14:42 | Insider Buys Of The Week: Arconic, CenturyLink, Hain Celestial and More
2019-03-08 16:32:33 | Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
2019-03-08 08:59:00 | Insider Buying Is Still Alive and Well at These 3 Companies
2019-03-08 02:08:55 | [$$] A disease in remission? New hope in the quest to cure HIV